For Healthcare Professionals:

Genetic Obesity ID | REGISTRY:
A registry for confirmed POMC and LEPR deficiency patients

We invite you to participate in a patient registry for POMC (pro-opiomelanocortin) or LEPR (leptin receptor) deficiency—two rare but important types of genetic, early-onset obesity. The goals of the Genetic Obesity ID | Registry are to:

  • Gain a more accurate and reliable assessment of the worldwide prevalence of obesity resulting in POMC and LEPR Deficiency
  • increase understanding of disease impact and progression

Rhythm is collaborating with healthcare providers to develop this registry as an international database that best supports the needs of patients and their healthcare providers.

Your participation in this registry requires the completion of a questionnaire survey that aims to determine the demographic characteristics of patients you have seen in your practice who have a genetically confirmed diagnosis of POMC or LEPR deficiency obesity—specifically, the presence of biallelic, pathogenic variants of either the POMC or PCSK1 genes; or the LEPR gene.

If you have diagnosed any patients with POMC or LEPR deficiency obesity, we would be very interested in having you register information about these patients. Also, we will be expanding this registry in coming months with a Patient Reported Questionnaire designed to compile information on the natural history of these genetic disorders. We will keep you apprised as we expand the questionnaire, which will further enhance the understanding of these important life-threatening disorders of obesity.

The Genetic Obesity Project is an initiative of Rhythm Pharmaceuticals, Inc. The content on this site is intended for use by patients, caregivers, and healthcare professionals for informational purposes only and is not intended to be taken as medical advice.
Back to Top